GlassScriptPhysician profile
Leslie A Phillips
NPI 1871748715
$1,847.90
in general payments reported to CMS, 2019-2025
21 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $204 · 2021: $120 · 2022: $124 · 2023: $397 · 2024: $281 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $607.53 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $247.39 | 2019-2025 | Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $158.07 | 2021-2024 | Acthar |
| Biotissue Holdings INC. | $106.99 | 2024 | |
| Dompe US, INC. | $91.12 | 2022-2025 | Oxervate |
| Rxsight INC | $77.88 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Coopervision INC. | $67.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $66.74 | 2021-2023 | Eylea |
| Optos, INC. | $56.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.75 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $47.28 | 2024 | Ultomiris |
| Allergan, INC. | $38.77 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $38.55 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $38.08 | 2021-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $35.21 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $30.99 | 2023 | |
| Oyster Point Pharma, INC. | $24.34 | 2023 | Tyrvaya |
| Genentech USA, INC. | $21.54 | 2023 | Vabysmo |
| Eyevance Pharmaceuticals LLC | $15.19 | 2019 | |
| Abbvie INC. | $14.37 | 2024 | |
| Ani Pharmaceuticals, INC. | $13.08 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.